Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Bioscienc (NQ: NBIX )

86.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 86.18
Bid (Size) 86.18 (2)
Ask (Size) 109.00 (1)
Prev. Close 86.18
Today's Range 86.18 - 86.18
52wk Range 71.88 - 108.02
Shares Outstanding 94,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Neurocrine Biosciences Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q1, Neurocrine Biosciences (NASDAQ:NBIX) earned $13.90 million, a 290.41% increase from the preceding quarter. Neurocrine Biosciences's sales decreased to $310.60... 
Via Benzinga
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
-2.59%
-2.59%
1 Month
-7.95%
-7.95%
3 Month
-1.73%
-1.73%
6 Month
+0.21%
+0.21%
1 Year
-10.05%
-10.05%

More News

Read More
Neurocrine Biosciences: Q1 Earnings Insights
Via Benzinga
Neurocrine Biosciences Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET
Via Benzinga
What 8 Analyst Ratings Have To Say About Neurocrine Biosciences
Via Benzinga
Analyst Ratings For Neurocrine Biosciences
Via Benzinga
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2022
Via Benzinga
Where Neurocrine Biosciences Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2022
Via Benzinga
Looking Into Neurocrine Biosciences's Return On Capital Employed
Via Benzinga
Why Neurocrine Biosciences Are Trading Higher Today?
Via Benzinga
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
Via Benzinga
Recap: Neurocrine Biosciences Q4 Earnings
Via Benzinga
Earnings Scheduled For February 11, 2022
Via Benzinga
A Preview Of Neurocrine Biosciences's Earnings
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022
Via Benzinga
Xenon Receives $15M Regulatory Milestone Under Epilepsy Pact With Neurocrine
Via Benzinga
Analyst Ratings For Neurocrine Biosciences
Via Benzinga
The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs
Via Benzinga
Expert Ratings For Neurocrine Biosciences
Via Benzinga
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Neurocrine's Ingrezza Meets Primary Goal In Phase 3 Study In Patients With Involuntary Muscle Movement
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.